Cowen Reiterates “Buy” Rating for Voyager Therapeutics (NASDAQ:VYGR)

Cowen reissued their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note published on Wednesday morning, AnalystRatings.com reports.

Other equities analysts have also issued research reports about the company. Zacks Investment Research raised Voyager Therapeutics from a hold rating to a buy rating and set a $19.00 price target for the company in a research report on Saturday, October 12th. ValuEngine lowered Voyager Therapeutics from a buy rating to a hold rating in a research report on Friday, October 25th. HC Wainwright reaffirmed a buy rating and issued a $26.00 price target on shares of Voyager Therapeutics in a research report on Monday, August 12th. Nomura reaffirmed a buy rating and issued a $37.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, August 13th. Finally, Morgan Stanley lowered their price target on Voyager Therapeutics from $28.00 to $26.00 and set an equal weight rating for the company in a research report on Friday, October 11th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Voyager Therapeutics has a consensus rating of Hold and a consensus target price of $27.71.

Shares of Voyager Therapeutics stock opened at $14.86 on Wednesday. The firm has a market capitalization of $548.84 million, a P/E ratio of -5.40 and a beta of 2.58. The business has a fifty day simple moving average of $15.86 and a two-hundred day simple moving average of $20.84. Voyager Therapeutics has a 12 month low of $7.76 and a 12 month high of $28.79.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.42. The business had revenue of $20.43 million during the quarter, compared to analyst estimates of $3.94 million. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. As a group, equities analysts expect that Voyager Therapeutics will post -1.95 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Voyager Therapeutics in the 2nd quarter worth about $27,000. Allianz Asset Management GmbH increased its holdings in Voyager Therapeutics by 16.5% in the 2nd quarter. Allianz Asset Management GmbH now owns 93,948 shares of the company’s stock worth $2,054,000 after buying an additional 13,339 shares in the last quarter. HM Payson & Co. bought a new stake in Voyager Therapeutics in the 2nd quarter worth about $63,000. Bailard Inc. bought a new stake in Voyager Therapeutics in the 2nd quarter worth about $1,116,000. Finally, JPMorgan Chase & Co. increased its holdings in Voyager Therapeutics by 28.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 326,643 shares of the company’s stock worth $8,590,000 after buying an additional 71,451 shares in the last quarter. 78.63% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

See Also: Risk Tolerance and Your Investment Decisions

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.